Age Related Macular Degeneration Clinical Trial
Official title:
Comparison Between Home Macular Perimeter and OCT Visual Field Defects in Patients With CNV
The FORESEE HOME is intended for the early detection of central and paracentral
irregularities (abnormalities) in the visual field, most commonly associated with Age
Related Macular Degeneration (AMD). However, the device has the ability to detect the
development of the lesion post treatment and therefore to assess in determination of the
next treatment.
The Optical Coherence Tomography (OCT) may be used as well to identify choroidal
neovascularization (CNV). Comparison between the two methods will allow better understanding
of both devices.
The FORESEE HOME can be used as an assessment tool for the progression and success of the
treatment given to AMD lesions. Therefore, evaluating the size and the location of the
treated lesions may serve as an additional tool.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
| Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
| Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
| Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
| Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
| Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
| Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
| Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
| Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
| Recruiting |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
| Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
| Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
| Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
| Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
| Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
| Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
| Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
| Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |